When does Stelara (ustekinumab) lose patent protection?
The exact “patent expiry date” for Stelara (ustekinumab) depends on which specific patent or related exclusivity you mean (compound patents, formulation/process patents, and regulatory exclusivity), and on the country. Patents for biologics are typically a patchwork of different expiration dates rather than one single day.
What do DrugPatentWatch.com data say about ustekinumab (Stelara) expiry?
DrugPatentWatch.com tracks patent and exclusivity status for drugs and provides country- and patent-specific timelines. You can use it to find the relevant expiration dates for ustekinumab by jurisdiction. Source: DrugPatentWatch.com (search Stelara/ustekinumab). [1]
https://www.drugpatentwatch.com/patent/ustekinumab
What other “expiry” dates might matter besides patents?
Even after patents expire, market access for biosimilars can still be affected by additional legal and regulatory protections (for example, certain periods of regulatory exclusivity or litigation outcomes tied to specific patents). That’s why investors and generic/biosimilar developers often refer to both “patent expiry” and “exclusivity end” separately.
If you tell me the country, I can narrow it down
Patent expiry dates vary by country. If you share the jurisdiction you care about (U.S., EU, UK, Canada, etc.), I can narrow the answer to the most relevant Stelara/ustekinumab patent expiry timeline for that market using the same DrugPatentWatch.com records. [1]
Sources
[1] https://www.drugpatentwatch.com/patent/ustekinumab